<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970385</url>
  </required_header>
  <id_info>
    <org_study_id>LTP 95</org_study_id>
    <nct_id>NCT00970385</nct_id>
  </id_info>
  <brief_title>Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma</brief_title>
  <acronym>LTP</acronym>
  <official_title>Multicentric Study About Treatment of High Grade Peripheral T Cell Lymphoma in Adults. LTP Study Comparison Between VIP ABVD Versus CHOP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter randomized trial evaluating induction treatment with
      VIP-reinforced-ABVD (VIP-rABVD) versus CHOP/21 in patients with newly diagnosed peripheral T
      cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction therapy:

      ARM 1: 6 Chemotherapy courses = 3 VIP alternated with 3 ABVD ARM 2: 8 Chemotherapy courses =
      CHOP every 21 days

      Consolidation therapy:

      For all patients if CR = radiotherapy 40GY / 5X1,8 GY per week
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1995</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between EFS rate of CHOP/21 versus VIP-rABVD in newly diagnosed PTCL.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate at the end of the treatment</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematotoxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Peripheral T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CHOP 21</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy CHOP every 21 days:
cyclophosphamide 750 mg/m2 intravenously (IV) day 1
doxorubicin 50 mg/m2 IV day 1
vincristine 1,4 mg/m2 (maximum 2 mg) day 1
prednisone 100 mg/m2/D from D1 to D5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIP/ABVD arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIP cycle:
etoposide 100 mg/m2/D IV from D1 to D3
ifosfamide 1000 mg/m2/D from D1 to D5
cisplatin 20 mg/m2/D as a continuous infusion from D1 to D5
ABVD cycle:
doxorubicin50 mg/m2/D on D1 and D14
bleomycin 10 mg/m2/D
vinblastine 10 mg/m2/D
dacarbazine 375 mg/m2/D Each alternating cycle was repeated three times for a total of 6 cycles (3 VIP, 3 rABVD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP21</intervention_name>
    <description>CHOP regimen:
cyclophosphamide 750 mg/m2 intravenously (IV) day 1
doxorubicin 50 mg/m2 IV day 1
vincristine 1,4 mg/m2 (maximum 2 mg) day 1
prednisone 100 mg/m2/D from D1 to D5.</description>
    <arm_group_label>CHOP 21</arm_group_label>
    <other_name>CHOP 21 arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIP/ABVD</intervention_name>
    <description>VIP regimen:
etoposide 100 mg/m2/D IV from D1 to D3
ifosfamide 1000 mg/m2/D from D1 to D5
cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5
ABVD regimen:
doxorubicin50 mg/m2/D on D1 and D14
bleomycin 10 mg/m2/D
vinblastine 10 mg/m2/D
dacarbazine 375 mg/m2/D</description>
    <arm_group_label>VIP/ABVD arm</arm_group_label>
    <other_name>VIP/ABVD Arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy consolidation</intervention_name>
    <description>The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.</description>
    <arm_group_label>CHOP 21</arm_group_label>
    <arm_group_label>VIP/ABVD arm</arm_group_label>
    <other_name>Consolidation treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed untreated PTCL

          -  age 18 and 70 years

          -  performance status ≤ 2

          -  Ann Arbor stage I to IV

          -  normal cardiac ventricular ejection fraction over 50%

          -  normal hepatic function (asat, ALAT, PAL &lt; 2.5 ULN)

        Exclusion Criteria:

          -  cutaneous form of PTCL

          -  previous treatment

          -  age &lt; 18 and &gt; 70

          -  performance status &gt; 2

          -  abnormal cardiac or hepatic functions

          -  HIV-, HCV- or HBV- positivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remy GRESSIN, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Grenoble GOELAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr REMY GRESSIN</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>September 8, 2009</last_update_submitted>
  <last_update_submitted_qc>September 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>CHU Grenoble/ Dr Rémy GRESSIN</name_title>
    <organization>GOELAMS</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

